Table 3.
Pivotal randomized controlled clinical trial for neoadjuvant chemotherapy in East Asia.
| Study | N | Published Year | Area | Setting | Disease Type | Recommended Resection | Treatment | Survival | HR | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| JCOG 0501 | 149 | 2021 | Japan | Borrmann type 3 (≧8 cm) | gastric 100% | D2/3 | NAC SP → Adj S-1 | 3-year OS: 62% | 0.916 | [27] |
| 151 | Borrmann type 4 | AC 100% | Adj S-1 | 3-year OS: 61% | ||||||
| PRODIGY | 238 | 2021 | Korea | Stage II/III | gastric 94%,GEJ 6% | D2 | NAC DOS → Adj S-1 | 3-year PFS: 66% | 0.69 | [29] |
| 246 | AC 100% | Adj S-1 | 3-year PFS: 60% | |||||||
| RESOLVE | 337 | 2021 | China | Stage III | gastric 64%, GEJ 36% | D2 | Perioperative SOX | 3-year DFS:59% | 0.77 | [30] |
| 340 | Adj SOX | 3-year DFS: 56% | ||||||||
| AC 100% | 0.86 | |||||||||
| 345 | Adj Capox | 3-year DFS:51% | ⁻ |
GEJ—gastroesophageal junction; AC—adenocarcinoma; OS—overall survival; PFS—progression-free survival; DFS—disease-free survival; Capox—capecitabine and oxaliplatin; SOX—S-1 and oxaliplatin; HR—hazard ratio.